Concord Drugs is a contract manufacturer that turns pharmaceutical formulas into finished pills, syrups and injectables - essentially a high-spec kitchen for drug companies. Founded in 1995 in Telangana and run by the Reddy family, it has spent three decades layering on new production lines at a single factory campus, most recently adding dry syrups in 2021. The recurring approach is to own the middle of the value chain - formulation development, pellet technology and fill-finish - so customers can hand over a recipe and receive shelf-ready medicine without building their own plant.
Business segments
A single-engine contract manufacturer organised around six production divisions and one differentiating technology - all operating from one site, serving the same customer type, and generating revenue from the same activity.
1. Finished-dose manufacturing: the company's sole revenue engine
Concord Drugs makes licensed medicines for other pharmaceutical companies under their brand names, earning a fee on every tablet, bottle and vial that leaves its factory.
- Six production lines under one roof - the factory houses dedicated divisions for tablets, syrups and injectables, each with its own production manager, so multiple customer orders can run in parallel without cross-contamination.
- End-to-end, from formula to finished pack - the company offers formulation development, manufacturing and fill-finish as a single service, which means a customer arrives with an approved drug formula and leaves with packaged, labelled stock ready for distribution.
- Revenue recognised on dispatch - the company books income when goods leave the factory gate and risk transfers to the buyer, measured after deducting returns, trade allowances and taxes, which is the standard trigger for a pure-play manufacturer.
- Raw materials dominate the cost base - the biggest expense is procuring APIs (active pharmaceutical ingredients) and other raw materials, so profitability hinges on buying well and running lines efficiently rather than on brand pricing power.
- One site, one geography - all manufacturing happens at the Brahmanapally village plant in Telangana, which simplifies quality oversight but also concentrates operational risk in a single location.
2. Pellet technology: the technical edge inside the factory
The company makes advanced drug-delivery pellets that control when and where a medicine releases in the body - a higher-value capability that sets it apart from basic tabletting shops.
- Timed-release coatings are the skill - Concord has in-house expertise in enteric coating (which protects drugs from stomach acid), sustained release, delayed release and immediate release formulations, using a technology platform called MUPS (Multiple Unit Pellet System).
- Sold as a standalone intermediate - customers can buy ready-to-fill pellets without ordering finished capsules, which creates a second product line from the same equipment and know-how.
- A dedicated division signals its importance - the pellets unit has its own production manager, separate from the tablets division, indicating it is treated as a distinct operational focus rather than a sideline.
Group structure and partners
Concord Drugs sits inside a family-run network of pharmaceutical trading and manufacturing entities, with a wholly owned distribution subsidiary and recurring transactions among related firms.
- A distribution arm that extends reach - Proton Remedies Private Limited, a wholly owned subsidiary acquired in March 2023, is a PCD (Propaganda Cum Distribution) company that markets third-party-manufactured products across therapy areas such as antibiotics, pain management and nutritional supplements.
- Related-party trade is woven into operations - the company buys and sells raw materials, packing materials and finished formulations with Proton Remedies Private Limited, with transaction limits proposed at ₹15 Crores for the coming year.
- Promoter family at the helm - Chairman S. Nagi Reddy and his two sons, who serve as whole-time directors and CFO, run the company, making it a classic family-controlled small-cap manufacturer.
- Banking relationship without borrowing - State Bank of India is the company’s banker, yet Concord has not availed any credit or guarantee facilities, suggesting it funds operations and upgrades through internal accruals and equity.